Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Kairos Pharma, LTD. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +4 vs. Q2 2025
- Shares held
- 445.0K
- +226.3K (+103.5%) vs. Q2 2025
- Total value
- $505.8K
- +$333.0K (+192.6%) vs. Q2 2025
- New holders
- 6
- 4 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KAPA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $371.1K |
| Q1 2026 | 11 | $341.5K |
| Q4 2025 | 14 | $607.5K |
| Q3 2025 | 14 | $505.8K |
| Q2 2025 | 10 | $172.9K |
| Q1 2025 | 8 | $1.46M |
| Q4 2024 | 5 | $618.3K |
| Q3 2024 | 2 | $70.0K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Kairos Pharma, LTD.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 304 | $356 | 0.00% | +253+496.1% | Added |
| Royal Bank of Canada | 1,000 | $1.00K | 0.00% | +1,000 | New |
| Tower Research Capital LLC (TRC) | 5,957 | $6.97K | 0.00% | +2,160+56.9% | Added |
| UBS Group AG | 5,979 | $7.00K | 0.00% | −3,479−36.8% | Reduced |
| XTX Topco Ltd | 12,408 | $14.5K | 0.00% | −50,338−80.2% | Reduced |
| Quadrature Capital Ltd | 14,887 | $17.4K | 0.00% | +14,887 | New |
| FNY Investment Advisers, LLC | 23,500 | $27.0K | 0.01% | +23,500 | New |
| State Street Corp | 24,100 | $28.2K | 0.00% | +24,100 | New |
| Two Sigma Securities, LLC | 24,895 | $29.1K | 0.00% | +11,340+83.7% | Added |
| SevenBridge Financial Group, LLC | 44,286 | $37.7K | 0.01% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 44,286 | $51.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 45,789 | $53.6K | 0.00% | +45,789 | New |
| Geode Capital Management, LLC | 65,800 | $77.0K | 0.00% | +43,996+201.8% | Added |
| Vanguard Group Inc | 131,828 | $154.2K | 0.00% | +131,828 | New |
| HRT Financial LP | 0 | $0 | 0.00% | −13,239−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −5,499−100.0% | Sold out |